Skip to content

A clinical trial to study the effects of two drugs methylprednisolone and dexamethasone in patients with severe COVID-19

Randomized Study Of the Effect of Dexamethasone and Methylprednisolone on levels of IL-6 and clinical outcome in severe COVID-19 - REDMIC

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026608
Enrollment
40
Registered
2020-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Injection Methylprednisolone: 1 mg/kg Intravenous once a day for 3 days Control Intervention1: Injection Dexamethasone: 6 mg intravenous once a day for 3 days

Sponsors

Dr Ananthakumar P K
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age more than 18 years old Both sex Lab. Confirmed COVID-19 cases with ARDS

Exclusion criteria

Exclusion criteria: Mild and moderate COVID-19 Severe immunosuppression (HIV infection, long-term use of immunosuppressive agents Pregnant or lactating women Patients already on steroids Patients with High Procalcitonin level

Design outcomes

Primary

MeasureTime frame
Primary outcomes: Difference in IL-6 level from baseline. Days to ventilator liberation Length of hospital stay (LOS). In-hospital all-cause mortality. The secondary outcomes Time to fever resolution Levels of bio-markers (CRP, D dimer, Ferritin) on Day 1 and Day 3. Timepoint: Day 1 and Day 3 for IL-6 level

Secondary

MeasureTime frame
patient details like baseline demographic data, laboratory reports â?? lymphocyte count, CRP, procalcitonin, Ferritin, D-dimer and clinical parameters including length of hospital stay and days in ventilator will be recorded before and after treatment with dexamethasone/methylprednisolone. Timepoint: from day 1 to day 3 for variation in CRP ferritin

Countries

India

Contacts

Public ContactDr Ananthakumar P K

Chettinad Academy of Research and Education

medicinehod@chettinadhealthcity.com9841210011

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026